Citations

Mayo Clinic

Showing 10 of 108522 citations.

Thrombotic microangiopathy and indications for therapeutic plasma exchange
Adamski, Jill

Hematology | November 24, 2014 | Volume: 2014 | Issue: 1 | Pages: 444-449

10.1182/asheducation-2014.1.444 | PMID 25696892 Get It

Abstract Thrombotic microangiopathy (TMA) is a clinicopathological condition associated with a wide variety of medical conditions. TMA is classically characterized by microangiopathic hemolytic anemia, thrombocytopenia, and microvascular thrombi that cause end-organ damage. The most prominent diagnoses associated with TMA are thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). Although TTP and HUS can have similar clinical and laboratory features and are often lumped together as a combined entity referred to as “TTP/HUS,” the pathologic processes causing TMA and optimal therapies for these conditions are different. Empiric use of therapeutic plasma exchange (TPE) in the setting of TMA is common. The high risk of morbidity and mortality associated with some causes of TMA justify rapid institution of this relatively low-risk procedure. However, many causes of TMA do not respond to TPE and prolonged courses of exchange in the absence of an underlying diagnosis may cause a detrimental delay in appropriate medical therapy. The American Society of Apheresis has published guidelines for the use of TPE for several distinct conditions associated with TMA. This list is not comprehensive and the use of TPE for other causes of TMA may be considered if the mechanism of the underlying disease process provides a clear rationale for this intervention.
Therapy for myeloproliferative neoplasms: when, which agent, and how?
Geyer, Holly L. , Mesa, Ruben A.

Hematology | November 24, 2014 | Volume: 2014 | Issue: 1 | Pages: 277-286

10.1182/asheducation-2014.1.277 | PMID 25696867 Get It

Abstract Myeloproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia, and myelofibrosis (MF) (both primary and secondary), are recognized for their burdensome symptom profiles, life-threatening complications, and risk of progression to acute leukemia. Recent advancements in our ability to diagnose and prognosticate these clonal malignancies have paralleled the development of MPN-targeted therapies that have had a significant impact on disease burden and quality of life. Ruxolitinib has shown success in alleviating the symptomatic burden, reducing splenomegaly and improving quality of life in patients with MF. The role and clinical expectations of JAK2 inhibition continues to expand to a variety of investigational arenas. Clinical trials for patients with MF focus on new JAK inhibitors with potentially less myelosuppression (pacritinib) or even activity for anemia (momelotinib). Further efforts focus on combination trials (including a JAK inhibitor base) or targeting new pathways (ie, telomerase). Similarly, therapy for PV continues to evolve with phase 3 trials investigating optimal frontline therapy (hydroxyurea or IFN) and second-line therapy for hydroxyurea-refractory or intolerant PV with JAK inhibitors. In this chapter, we review the evolving data and role of JAK inhibition (alone or in combination) in the management of patients with MPNs.
A practical approach to relapsed multiple myeloma
Mıkhael, Joseph , Mikhael, Joseph R.

Hematology | November 24, 2014 | Volume: 2014 | Issue: 1 | Pages: 262-267

10.1182/asheducation-2014.1.262 | PMID 25696865 Get It

Abstract There has been tremendous progress made in multiple myeloma in the last decade, resulting in improved overall survival for all patients, including those with high-risk disease and those ineligible for transplantation. However, despite the addition of several novel agents, unprecedented response rates, and our ability to achieve complete remission in the majority of patients, the disease remains incurable in nearly all and will require repeated therapies. With many options available to the clinician, there is no simple or ideal sequence of treatments that has been established, so the choice of relapsed therapy is based on a series of factors that include response and tolerability of prior therapies, risk status, available novel agents, aggressiveness of relapse, renal function, performance status, cost, etc. This chapter provides practical guidance in selecting relapsed therapies structured through a series of 5 questions that can inform the decision. Specific emphasis is placed on the 2 most recent novel agents, carfilzomib and pomalidomide, but agents in development are also included.
Therapeutic targeting of microenvironment in follicular lymphoma
Nowakowski, Grzegorz S. , Ansell, Stephen M.

Hematology | November 24, 2014 | Volume: 2014 | Issue: 1 | Pages: 169-173

10.1182/asheducation-2014.1.169 | PMID 25696851 Get It

AbstractImmune and nonimmune microenvironmental factors play a critical role in the progression, transformation, and resistance to therapy in follicular lymphoma (FL). A recent increase in our understanding of the role of microenvironment in FL biology has led to the development of novel therapeutic strategies targeting the nonimmune and immune microenvironment. These include immunomodulatory drugs, immune checkpoint inhibitors, immnunoconjugates, and small-molecule inhibitors with an impact on the microenvironment in addition to direct antitumor activity. These agents are now at different stages of clinical development, ranging from early clinical trials in relapsed disease to phase 3 studies in the upfront setting, including combinations with other agents such as monoclonal antibodies and chemotherapy. It is important to recognize that, although the current upfront therapy of FL is associated with favorable outcomes in the majority of patients, a significant proportion experience early disease progression and develop treatment resistance and transformation to aggressive lymphoma. Although the development of “chemo-free” combinations using drugs targeting the microenvironment offers a promising approach to minimize toxicity, the identification of patients at risk of relapse and the use of biomarkers allowing the personalization of therapy will likely play a major role in the development of maintenance strategies. Against this landscape of currently available therapy options, this chapter discusses the clinical status of therapies targeting the microenvironment in FL.
Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis
Foureau, David , Walling, Tracy L., Maddukuri, Vinaya C. , Anderson, William E. , Culbreath, Katherine , Ahrens, Will, Jacobs, C., Watkins, Paul B. , Chalasani, Naga , Talwalkar, Jayant A., Lee, W.M., Stolz, Andrew , Bonkovsky, Herbert L. , Kleiner, David Erwin , Fontana, Robert J. , Serrano, José , Foureau, David

Clinical and Experimental Immunology | November 23, 2014 | Volume: 180 | Issue: 1 | Pages: 40-51

10.1111/cei.12558 | PMID 25418487 Get It

Summary Drug-induced liver injury (DILI) is often caused by innate and adaptive host immune responses. Characterization of inflammatory infiltrates in the liver may improve understanding of the underlying pathogenesis of DILI. This study aimed to enumerate and characterize leucocytes infiltrating liver tissue from subjects with acute DILI (n = 32) versus non-DILI causes of acute liver injury (n = 25). Immunostains for CD11b/CD4 (Kupffer and T helper cells), CD3/CD20 (T and B cells) and CD8/CD56 [T cytotoxic and natural killer (NK) cells] were evaluated in biopsies from subjects with acute DILI, either immunoallergic (IAD) or autoimmune (AID) and idiopathic autoimmune (AIH) and viral hepatitis (VH) and correlated with clinical and pathological features. All biopsies showed numerous CD8+ T cells and macrophages. DILI cases had significantly fewer B lymphocytes than AIH and VH and significantly fewer NK cells than VH. Prominent plasma cells were unusual in IAD (three of 10 cases), but were associated strongly with AIH (eight of nine) and also observed in most with AID (six of nine). They were also found in five of 10 cases with VH. Liver biopsies from subjects with DILI were characterized by low counts of mature B cells and NK cells in portal triads in contrast to VH. NK cells were found only in cases of VH, whereas AIH and VH both showed higher counts of B cells than DILI. Plasma cells were associated most strongly with AIH and less so with AID, but were uncommon in IAD.
Mortality after Radical Cystectomy: Impact of Obesity Versus Adiposity after Adjusting for Skeletal Muscle Wasting
Psutka, Sarah P. , Boorjian, Stephen A. , Moynagh, Michael R., Schmit, Grant D. , Frank, Igor, Carrasco, Alonso , Stewart, Suzanne, Tarrell, Robert F., Thapa, Prabin , Tollefson, Matthew K. , Stewart, Suzanne B, Tarrell, Robert, Psutka, Sarah P

Journal of Urology | November 22, 2014 | Volume: 193 | Issue: 5 | Pages: 1507-1513

10.1016/j.juro.2014.11.088 | PMID 25464002 Get It

Ventricular Arrhythmia Risk Stratification in Patients With Tetralogy of Fallot at the Time of Pulmonary Valve Replacement
Sabaté-Rotés, Anna , Connolly, Heidi M. , Warnes, Carole A. , Ammash, Naser M., Phillips, Sabrina D. , Schaff, Hartzell V. , Burkhart, Harold M. , Hodge, David O. , Asirvatham, Samuel J. , Dearani, Joseph A. , McLeod, Christopher J. , Asirvatham, Samuel J , Schaff, Hartzell

Circulation: Arrhythmia and Electrophysiology | November 21, 2014 | Volume: 8 | Issue: 1 | Pages: 110-116

10.1161/circep.114.001975 | PMID 25416756 Get It

Background— Most patients with repaired tetralogy of Fallot require pulmonary valve replacement (PVR), but the evaluation for and management of ventricular arrhythmia remain unclear. This study is aimed at clarifying the optimal approach to this potentially life-threatening issue at the time of PVR. Methods and Results— A retrospective analysis was performed on 205 patients with repaired tetralogy of Fallot undergoing PVR at our institution between 1988 and 2010. Median age was 32.9 (range, 25.6) years. Previous ventricular tachycardia occurred in 16 patients (8%) and 37 (16%) had left ventricular dysfunction, defined as left ventricular ejection fraction <50%. Surgical right ventricular outflow tract cryoablation was performed in 22 patients (10.7%). The primary outcome was a combined event including ventricular tachycardia, out-of-hospital cardiac arrest, appropriate implantable cardioverter defibrillator therapy, and sudden cardiac death. Freedom from the combined event at 5, 10, and 15 years was 95%, 90%, and 79%, respectively. In the first year after PVR, 2 events occurred. Conversely, in the 22 patients who underwent surgical cryoablation, a single event occurred 7 years after PVR. A history of ventricular tachycardia and left ventricular dysfunction was associated with higher risk for the combined event (hazard ratio, 4.7; P =0.004 and hazard ratio, 0.8; P =0.02, respectively). Conclusions— Patients with repaired tetralogy of Fallot undergoing PVR with history of ventricular tachycardia or left ventricular dysfunction appear to be associated with a higher risk of arrhythmic events after operation. Events in the first year after PVR are rare, and in select high-risk patients, surgical cryoablation does not seem to increase arrhythmic events and may be protective.
Delayed primary excision with subsequent modification of radiotherapy dose for intermediate‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee
Rodeberg, David A. , Wharam, Moody D., Lyden, Elizabeth , Stoner, Julie A., Brown, Kenneth L., Paidas, Charles N. , Donaldson, Sarah S. , Hawkins, Douglas S. , Spunt, Sheri L. , Arndt, Carola A.S., Wolden, Suzanne L. , Hawkins, Douglas S , Spunt, Sheri L , Donaldson, Sarah S

International Journal of Cancer | November 21, 2014 | Volume: 137 | Issue: 1 | Pages: 204-211

10.1002/ijc.29351 | PMID 25418440 Get It

The majority of intermediate‐risk rhabdomyosarcoma (RMS) patients have gross residual disease (Group III) after their first operative procedure. It is currently not known if local control rates can be maintained when, following induction chemotherapy, the radiation therapy (RT) dose is decreased after a delayed primary excision (DPE). To answer this question we evaluated patients enrolled on COG D9803 (1999–2005) who had Group III tumors of the bladder dome, extremity or trunk (thorax, abdomen and pelvis) were candidates for DPE at Week 12 if the primary tumor appeared resectable. RT dose was then adjusted by the completeness of DPE: no evidence of disease 36 Gy, microscopic residual 41.4 Gy and gross residual disease (GRD) 50.4 Gy. A total of 161 Group III patients were evaluated (24 bladder dome, 63 extremity and 74 trunk). Seventy‐three patients (45%) underwent DPE which achieved removal of all gross disease in 61 (84%) who were then eligible for reduced RT dose (43/73 received 36 Gy, 19/73 received 41.4 Gy). The local 5‐year failure rate (0% for bladder dome, 7% for extremity and 20% for trunk) was similar to IRS‐IV, which did not encourage DPE and did not allow for DPE adapted RT dose reduction. In conclusion, DPE was performed in 45% of Group III RMS patients with tumors at select anatomic sites (bladder dome, extremity and trunk) and 84% of those who had DPE were eligible for RT dose reduction. Local control outcomes were similar to historic results with RT alone.
CT Colonography for the Detection of Nonpolypoid Adenomas: Sensitivity Assessed With Restricted National CT Colonography Trial Criteria
Fidler, Jeff L. , Zhang, Zheng , Herman, B. , Dachman, Abraham H. , Heiken, Jay P. , Kuo, Mark , Menias, Christine O. , Siewert, Bettina , Cheema, Jugesh I., Obregon, Richard G., Zimmerman, Peter, Horton, Karen M., Iyer, Revathy B., Hara, Amy K., Halvorsen, Robert A., Casola, Giovanna, Burgart, Lawrence J., Johnson, C. Daniel, Fidler, Jeff L. , Limburg, Paul J. , Fletcher, Joel G. , Coakley, Kevin J. , Yee, Judy

American Journal of Roentgenology | November 21, 2014 | Volume: 203 | Issue: 6 | Pages: W614-W622

10.2214/ajr.13.12356 | PMID 25415726 Get It

Are there modifiable risk factors to prevent a cerebrospinal fluid leak following vestibular schwannoma surgery?
Copeland, William R., Mallory, Grant W., Neff, Brian A., Driscoll, Colin L. W., Link, Michael J.

Journal of Neurosurgery | November 21, 2014 | Volume: 122 | Issue: 2 | Pages: 312-316

10.3171/2014.10.jns14432 | PMID 25415063 Get It

OBJECT The following study was conducted to identify risk factors for a postoperative CSF leak after vestibular schwannoma (VS) surgery. METHODS The authors reviewed a prospectively maintained database of all patients who had undergone resection of a VS at the Mayo Clinic between September 1999 and May 2013. Patients who developed a postoperative CSF leak within 30 days of surgery were compared with those who did not. Data collected included patient age, sex, body mass index (BMI), tumor size, tumor side, history of prior tumor treatment, operative time, surgical approach, and extent of resection. Both univariate and multivariate regression analyses were performed to evaluate all variables as risk factors of a postoperative CSF leak. RESULTS A total of 457 patients were included in the study, with 45 patients (9.8%) developing a postoperative CSF leak. A significant association existed between increasing BMI and a CSF leak, with those classified as overweight (BMI 25–29.9), obese (BMI 30–39.9), or morbidly obese (BMI ≥ 40) having a 2.5-, 3-, and 6-fold increased risk, respectively. Patients undergoing a translabyrinthine (TL) approach experienced a higher rate of CSF leaks (OR 2.5, 95% CI 1.3–4.6; p = 0.005), as did those who had longer operative times (OR 1.04, 95% CI 1.02–1.07; p = 0.0006). The BMI, a TL approach, and operative time remained independent risk factors on multivariate modeling. CONCLUSIONS Elevated BMI is a risk factor for the development of a postoperative CSF leak following VS surgery. Recognizing this preoperatively can allow surgeons to better counsel patients regarding the risks of surgery as well as perhaps to alter perioperative management in an attempt to decrease the likelihood of a leak. Patients undergoing a TL approach or having longer operative times are also at increased risk of developing a postoperative CSF leak.